Studying Predictors and Glucose Monitoring in Steroid-Induced Diabetes
Follows adults starting steroid medicine, using continuous glucose monitors to study steroid-induced diabetes.
Plain-language title generated from the registry record
Registry title: Predictive Factors and Monitoring Strategies in Steroid-Induced Diabetes
Key facts
- Where
- Warsaw, PolandSee the site
Where in Poland
- Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, PolandWarsaw, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Warsaw
- Trial code
- NCT07190378
- Record updated
- 1 October 2025
- Original description
Glucocorticoids are widely used in the management of autoimmune, inflammatory and neoplastic conditions. However, they are associated with significant metabolic effects, including steroid-induced diabetes (SID). SID is typically diagnosed using general criteria for type 2 diabetes, which may be inadequate due to the unique glycemic profile often seen in SID, where postprandial hyperglycemia predominates. This research aims to explore the diagnostic value of CGM during steroid therapy and identify risk factors for SID This is a prospective observational study (n=250) enrolling adults initiating glucocorticoid therapy. Participants will undergo 14-day continuous glucose monitoring (CGM) to assess predictive factors and glycemic profile.Read full original descriptionShow less
Predictive Factors of Steroid-Induced Diabetes and the Role of Continuous Glucose Monitoring in the Diagnosis and Metabolic Control of the Disease
Glucocorticoids are widely used in the management of autoimmune, inflammatory and neoplastic conditions. However, they are associated with significant metabolic effects, including steroid-induced diabetes (SID). SID is typically diagnosed using general criteria for type 2 diabetes, which may be inadequate due to the unique glycemic profile often seen in SID, where postprandial hyperglycemia predominates. This research aims to explore the diagnostic value of CGM during steroid therapy and identify risk factors for SID This is a prospective observational study (n=250) enrolling adults initiating glucocorticoid therapy. Participants will undergo 14-day continuous glucose monitoring (CGM) to assess predictive factors and glycemic profile.
Inclusion: Adults (≥18 years of age); No prior diagnosis of diabetes; Planned initiation of oral and/or intravenous glucocorticoid therapy for non-substitutive indications; Informed consent.
Exclusion: GC therapy within the past 6 months; History of diabetes or use of antidiabetic medications; Replacement therapy for primary or secondary adrenal insufficiency, pituitary insufficiency, Nelson's syndrome, or congenital adrenal hyperplasia; Age <18 years; Lack of consent.